---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-004254"
form_type: "8-K"
ticker: "XFOR"
cik: "0001501697"
company_name: "X4 Pharmaceuticals, Inc"
filed_at: "2025-02-06T23:59:59+00:00"
generated_at: "2026-05-27T01:36:00.832219+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# X4 Pharmaceuticals cuts 30% of workforce, closes Vienna facility, expects $30-35M annual savings

## Summary
- Headcount reduced by 43 (~30%); Vienna facility closed; preclinical programs paused.
- Estimated $3.0M in severance charges, primarily in Q1 2025.
- Annual spending expected to decrease by $30-35M; cash runway into first half 2026.
- Phase 3 trial for mavorixafor in chronic neutropenia enrollment on track for mid-2025.
- Focus on advancing mavorixafor for chronic neutropenia and optimizing XOLREMDI promotion for WHIM.

## SEC filing metadata
- accession: 0001628280-25-004254
- form_type: 8-K
- ticker: XFOR
- cik: 0001501697
- company_name: X4 Pharmaceuticals, Inc
- filed_at: 2025-02-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.05, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501697/000162828025004254/0001628280-25-004254-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501697/000162828025004254/xfor-20250206.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-004254
- JSON: https://secwatch.observer/filing/0001628280-25-004254.json
- Plain text: https://secwatch.observer/filing/0001628280-25-004254.txt

## Key facts
- Restructurings & Charges
  X4 Pharmaceuticals, Inc announced a restructuring with charges of approximately $3.0 million for severance and other employee termination-related costs affecting the Company (43 employees, or approximately 30% of the Company’s employees).
  - Type: restructuring
  - Charge: approximately $3.0 million for severance and other employee termination-related costs
  - Affected area: the Company
  - Headcount: 43 employees, or approximately 30% of the Company’s employees
  source text: The Company estimates that it will incur charges of approximately $3.0 million for severance and other employee termination-related costs, primarily in the first quarter of 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501697/000162828025004254/0001628280-25-004254-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.